实体器官移植中贝拉西普及其他生物制剂的治疗药物监测潜力
本文综述实体器官移植中生物制剂(包括贝拉西普等)的应用证据,探讨治疗药物监测(TDM)和模型引导精准给药(MIPD)的改进潜力。部分药物如阿仑单抗、依库珠单抗、利妥昔单抗、托珠单抗和贝拉西普已显示显著药代动力学个体间变异,但缺乏足够效力的试验证明TDM和MIPD改善临床结局。
要点
- 生物制剂在实体器官移植中多超说明书使用,剂量多为标准给药。
- 贝拉西普等药物药代动力学个体间变异显著,皮下吸收变异可能增加变异性。
- 现有TDM和MIPD研究多为概念验证或可行性研究,缺乏足够效力。
核心结论
- 生物制剂在实体器官移植中超说明书使用普遍,TDM和MIPD的临床获益尚缺乏足够证据。
- 部分生物制剂药代动力学个体间变异显著,但支持TDM改善结局的试验稀缺。
研究设计与样本
- 综述,回顾实体器官移植中生物制剂的医学证据及TDM和MIPD的应用潜力。
主要发现
- 阿仑单抗、依库珠单抗、利妥昔单抗、托珠单抗和贝拉西普的研究显示药代动力学显著个体间变异。
- 皮下给药的吸收变异可能增加个体间变异。
- TDM和MIPD的个体化研究多为概念验证或可行性研究,缺乏证明临床结局改善的效力。
- 适当给药还涉及经济方面。
临床怎么用
- 生物制剂在实体器官移植中多按标准剂量使用,超说明书应用需谨慎。
- 现有检测方法和模型可用于优化解释,但需足够样本量的试验验证TDM和MIPD的实用性。
- 建议通过TDM社区协作开展研究,确定TDM可能获益的场景。
局限性
- 缺乏足够效力的试验记录TDM和MIPD的实用性。
- TDM和MIPD的个体化研究多为概念验证或可行性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In solid organ transplantation (SOT), biologicals such as recombinant therapeutic proteins, monoclonal antibodies, fusion proteins and conjugates are increasingly used for immunosuppression, desensitization, ABO (blood group) incompatibility, antibody-mediated rejections and atypical haemolytic uremic syndrome. In this paper, we review the medical evidence available for biologicals used in SOT and the potential for improvement by the application of therapeutic drug monitoring (TDM) and model-informed precision dosing. Biologicals are used for off-label indications within the field of SOT, building on the experience from their use on labelled indications. Dosing is currently mostly standard, and experience vs. effect and toxicity is limited. Pharmacokinetic characteristics of these large, partly also immunogenic molecules differ from those of traditional small molecules. Individualization by concentration measurements and modelling has mostly been proof-of-concept or feasibility studies that lack the power to provide evidence for improvement in clinical outcome. For some drugs such as alemtuzumab, eculizumab, rituximab, tocilizumab and belatacept, studies have demonstrated significant interindividual variability in pharmacokinetics. Variability in absorption from subcutaneous administration may increase interindividual variability. There is also an economic aspect of appropriate dosing that needs to be pursued. Available assays and models to refine interpretation are in place, but trials of adequate size to document the usefulness of TDM and MIPD are scarce. Collaboration within the TDM community seems mandatory to establish studies of sufficient strength to provide evidence for the use of biologicals that are currently used off-label in SOT and furthermore to identify the settings where TDM may be beneficial.
引用
- Bergan S, Vethe NT. The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation. Br J Clin Pharmacol. 2024. PMID: 39056476. doi:10.1111/bcp.16170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。